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Farnesoid X receptor activation 
protects the kidney from  
ischemia-reperfusion damage
Zhibo Gai1, Lei Chu2, Zhenqiang Xu3, Xiaoming Song4, Dongfeng Sun4 & Gerd A. Kullak-Ublick  1
Farnesoid X receptor (FXR) activation has been reported to reduce inflammation and oxidative stress. 
Because both inflammation and oxidative stress are critical for tissue destruction during kidney 
ischemia reperfusion (I/R) injury, we investigated the protective role of FXR against kidney damage 
induced by I/R in mice. Mice undergoing renal I/R developed the typical features of acute kidney injury 
(AKI): increased creatinine, albuminuria, tubular necrosis and apoptosis. Inflammatory cytokine 
production and oxidative stress were also markedly increased. In mice pretreated with 6-ethyl-
chenodeoxycholic acid (6-ECDCA), a selective FXR agonist, I/R induced changes were prevented and 
renal function and structure were improved. Moreover, FXR activation also effectively prevented the 
subsequent progression of AKI to chronic kidney disease (CKD) by ameliorating glomerulosclerosis and 
interstitial fibrosis and by suppressing fibrogenic gene expression. FXR mRNA levels were inversely 
correlated with the progression to CKD in mice and with the degree of interstitial fibrosis in human 
biopsies. In further experiments administering 6-ECDCA to renal proximal tubular cells cultured under 
hypoxia, the renoprotective effects of FXR activation were associated with inhibition of oxidative and 
ER stress and with increased antioxidant activity. In conclusion, FXR agonists may have a therapeutic 
role in conditions associated with ischemic kidney damage.
Acute kidney injury (AKI) is a common complication in patients undergoing major cardiac surgery, those receiv-
ing nephrotoxic drugs and those experiencing hemorrhage, dehydration or septic shock1. AKI is characterized 
by an abrupt decrease in the glomerular filtration rate and is a common surgical complication leading to an 
unacceptably high mortality, chronic kidney disease (CKD) and end stage renal disease (ESRD)2. Renal ischemia 
reperfusion (I/R) injury involves a complex and interrelated sequence of events resulting in renal cell damage 
and, eventually, cell death by apoptosis and necrosis3. Although reperfusion is essential for survival of ischemic 
tissues, reperfusion itself causes additional cellular injury. This has been attributed to neutrophil infiltration and 
generation of reactive oxygen species (ROS)4–6.
The molecular mechanisms underlying I/R injury are incompletely understood. Diminished oxygen delivery, 
an accumulation of toxic products in kidney cells and cytokine release play important roles7, 8. In addition, ROS 
generation is critical and is believed to cause tubular epithelial cell damage and death by apoptosis and necrosis9, 10. 
Clinical and experimental studies showed that ROS are crucial for tissue damage and cell apoptosis during I/R, 
particularly during the process of reperfusion11–13. ROS cause lipid peroxidation, disrupting structural integrity 
and energy production, especially in the proximal tubular segment, which is highly susceptible to acute ischemia 
and hypoxia14, 15. During the process of I/R, the mitochondria and endoplasmic reticulum (ER) are major ROS 
targets, with outcomes including altered redox homeostasis, mitochondrial damage and protein misfolding in the 
ER16. Several studies closely linked ER stress and mitochondrial dysfunction to the pathogenesis of kidney I/R 
injury17.
Ischemic kidney injury is not always reversible and can lead to ESRD or exacerbate other underlying disease 
processes, accelerating their progression to end stage kidney failure18. In the mouse, a short ischemic episode can 
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lead to persistent interstitial fibrosis19 and, in humans, acute ischemic insult occurring immediately after kidney 
transplantation or cardiovascular bypass may delay recovery of kidney function and lead to chronic nephropa-
thy20, 21. Experimental mouse I/R injury has been used extensively to study the pathogenesis of ischemic injury. 
Although its pathogenesis has become better defined, few therapeutic options are currently available to ameliorate 
I/R injury22–25.
FXR is a member of the nuclear receptor superfamily of ligand-activated transcription factors and functions 
as an endogenous bile acid sensor26. Evidence suggests that the most potent natural activator of human FXR 
is chenodeoxycholic acid (CDCA). 6-Ethyl-chenodeoxycholic acid (6-ECDCA), with an alkyl substitution that 
increases its receptor affinity, is a more potent FXR agonist than CDCA27. It was recently reported that FXR acti-
vation decreased the inflammatory damage and ROS accumulation closely associated with the pathophysiology 
of renal diseases28–30. Therefore, we hypothesized that FXR activation would alleviate renal I/R injury by protect-
ing the mitochondria and ER from ROS and restoring the balance of oxidation and anti-oxidation systems. Our 
results showed that FXR activation by the FXR agonist 6-ECDCA prevented renal I/R injury, indicating that FXR 
agonists may have a therapeutic role in conditions associated with ischemic kidney damage.
Results
FXR is localized in the nuclei of proximal tubular cells and levels are decreased during I/R damage. 
To examine the precise localization of FXR protein in the kidneys of adult mice and humans, we performed 
immunostaining for FXR, observing positive staining in the tubular epithelial cells of the cortex region (Fig. 1A). 
To further characterize FXR localization, an antibody directed against villin, a specific marker for the brush bor-
der of proximal tubules, was also used for double immunostaining. The villin positive area was restricted to the 
cortex regions where there was also FXR staining. FXR was co-localized with villin in proximal tubular epithelial 
cells (Fig. 1B).
To assess the role of FXR in renal I/R injury, kidney clamping for 30 minutes was followed by reperfusion. 
Sampling was undertaken at various time points thereafter. We first determined levels of FXR mRNA and pro-
tein in renal tissue and found that both were decreased 24 h after reperfusion (Fig. 1C and D). FXR mRNA 
levels remained decreased for up to 3 d and then returned to normal levels. Similar findings were observed in 
preimplantation biopsies from individuals with acute ischemic damage (Fig. 1E). The results showed that FXR 
expression was significantly lower in ischemic kidneys, suggesting that FXR activation was potentially protective 
during kidney I/R injury.
FXR activation mitigates I/R injury and improves renal function after reperfusion. We pre-
viously reported that FXR activation protects kidney from obesity-induced damage28. In exploring the in vivo 
effects of FXR activation, we found that oral and intraperitoneal (i.p.) delivery of 6-ECDCA, an FXR specific 
agonist, produced very different effects (Fig. S1A). The i.p. injection of 6-ECDCA (5 mg/kg) led to induction of 
the FXR target gene Shp (Nr0b2) in the kidney, whereas oral administration at the same dosage did not induce 
Shp expression. To determine the appropriate dosage of 6-ECDCA, we performed a dose response experiment. 
mRNA expression levels of Shp were induced in the kidney after a single i.p. injection of 6-ECDCA at 5 mg/kg or 
10 mg/kg. Our results are consistent with previous studies showing that i.p. injection of an FXR agonist provides 
more efficient FXR activation in the kidney31 and 5 mg/kg of 6-ECDCA are sufficient to activate FXR in the kid-
ney32. Unless stated otherwise, 5 mg/kg of 6-ECDCA was used in this study.
Next, to investigate the effects of FXR activation during kidney injury, we injected mice with 6-ECDCA 24 h 
before inducing ischemia. 6-ECDCA treatment activated FXR sufficiently, as shown by induction of its target genes 
(Fig. 2A). Renal function was assessed by serum BUN and creatinine. Renal I/R produced a marked increase in 
serum BUN and creatinine, and all of these effects were attenuated in mice pretreated with 6-ECDCA (Fig. 2B and C). 
However, serum BUN and creatinine levels in the 6-ECDCA treatment alone group (sham-ECDCA) were iden-
tical to the sham group. We next examined how the timing of 6-ECDCA injection affected its protection against 
I/R. 6-ECDCA injection at either 2 or 8 h before I/R significantly attenuated kidney injury by decreasing serum 
creatinine (Fig. S2A). In a separate experiment, to examine whether 6-ECDCA had renoprotective effects after 
the onset of reperfusion injury, we injected the compound 30 min after I/R and observed a small, but significant, 
decrease in serum creatinine (Fig. S2A). Therefore, 6-ECDCA was most effective when injected before I/R but 
had a partial benefit when administered after the onset of reperfusion injury. Similar renoprotective effects were 
observed with GW4064, another FXR agonist. GW4064 treatment significantly attenuated I/R-induced renal 
dysfunction (Fig. S2B and C). GW4064 also significantly improved the histological scores observed in mice after 
I/R (Fig. S2B).
Histological analysis showed typical features of severe tubular damage in the I/R group, including loss of the 
brush border and extensive tubular necrosis (Fig. 2D b). We introduced a scoring system to compare the severity 
of I/R injury between groups. The tubular injury scores in kidneys subjected to I/R were markedly greater than 
in those of sham mice (Fig. 2F). Pretreatment with 6-ECDCA preserved the normal morphology of the kidney 
and resulted in only a slight loss of the brush border. In addition, the 6-ECDCA pretreated mice also had less 
severe tubular necrosis (Fig. 2D c). Quantification of tubular injury by immunostaining for Kim-1 correlated 
with renal function and histological findings. As compared with the sham mice, the kidneys of I/R mice showed 
extensive Kim-1 staining in the proximal tubules (Fig. 2E b and G). However, with 6-ECDCA pretreatment there 
was negligible Kim-1 staining in the tubules (Fig. 2E c). Both histological analysis and Kim-1 staining results 
in the 6-ECDCA treatment alone group (sham-ECDCA) were identical to the sham group (Fig. 2D d and E d, 
respectively), consistent with serum BUN and creatinine levels (Fig. 2B and C). Therefore, we focused on the 
comparison between the I/R group and the I/R + ECDCA group in the subsequent studies.
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FXR activation decreases inflammation and apoptosis in I/R injured kidney tissue. The inflam-
matory response following I/R injury is known to be related to renal dysfunction15. To investigate whether the 
improved renal function in 6-ECDCA pretreated mice was dependent on a suppressed inflammatory reaction, 
we stained kidney tissues for CD4 and tumor necrosis factor alpha (TNFα). After 24 h reperfusion, the number of 
CD4+ cells was increased in kidneys of mice that had been subjected to only I/R (Fig. 3A b). Levels of the inflam-
matory cytokine TNFα were also increased in these kidneys (Fig. 3B b). However, staining for both CD4 and 
TNFα was significantly decreased in 6-ECDCA pretreated mice (Fig. 3A c and 3B c, respectively). Real-time PCR 
Figure 1. FXR is localized to the proximal tubules of adult mouse kidney cortex and its expression is decreased 
after ischemia reperfusion. (A) Immunohistochemistry for FXR (scale bar 100 μm). FXR was specifically 
localized to the nuclei of proximal tubular epithelial cells. (B) Double immunofluorescence staining of mouse 
kidneys with antibodies for FXR (red) and villin (green), scale bar 50 μm. Note the extensive co-localization of 
FXR and villin in the proximal tubules of the cortex. Nuclei were stained with DAPI (blue). (C) Levels of FXR 
mRNA in the kidney from sham and I/R treatment groups at various timepoints. (D) Representative western 
blots showing mouse kidney lysates from the two treatment groups. (E) Levels of FXR mRNA from normal and 
pretransplantation human kidney biopsies. I/R, ischemia reperfusion; AKI, acute kidney injury. n = 6 mice/
group. Data are means ± SEM, one-way ANOVA with Bonferroni’s test. *p < 0.05.
www.nature.com/scientificreports/
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analysis confirmed that the 6-ECDCA pretreated I/R group had less inflammation than the I/R group (Fig. 3C). 
Changes in serum TNFα and MCP-1 levels were consistent with the changes of TNFα and MCP-1 mRNA levels, 
which were significantly increased in the I/R kidney and ameliorated by 6-ECDCA treatment (Fig. 3D and E). 
ICAM, a cell surface glycoprotein induced by interleukin-1 and TNFα in leukocytes, was increased in the I/R 
kidneys. However, this increase was attenuated by FXR activation (Fig. 3I).
Apoptosis is a major mediator of tubular cell death after renal I/R injury. To investigate whether the protec-
tive effect of FXR activation in renal injury involved decreased apoptosis, the extent of kidney apoptosis was 
evaluated by TUNEL staining (Fig. 3F). The number of TUNEL-positive apoptotic cells was markedly greater in 
I/R mice than in sham mice (Fig. 3F b, indicated by arrows, and 3 G). After I/R, the kidneys also had increased 
levels of proapoptotic caspase-3 and Bax, decreased mRNA for the anti-apoptotic factor Bcl2 (Fig. 3H) and 
increased cleaved-caspase-3 protein level (Fig. 3I). Pretreatment with 6-ECDCA attenuated these changes 
(Fig. 3F c, H and I).
Figure 2. Protection against renal I/R injury by a FXR agonist. Mice were injected i.p. with 6-ECDCA before 
I/R injury. At 24 h after I/R, kidney, serum and urine samples were collected for measurements of (A) FXR 
target gene expression in kidney, (B) BUN in serum, (C) creatinine in serum. (D) Representative images 
showing HE staining on renal sections from (a) sham, (b) I/R, (c) I/R + ECDCA and (d) sham + ECDCA 
groups (scale bar 50 μm). (E) Representative images showing Kim1 immunostaining in renal sections from (a) 
sham, (b) I/R, (c) I/R + ECDCA and (d) sham + ECDCA groups (scale bar 50 μm). Kim1 is specifically localized 
in the proximal tubules. (F) Quantitative analysis of tubular injury scores. n = 6 mice/group. (G) Quantitative 
analysis of Kim1 positive staining per high power field. n = 6 mice/group. Data are means ± SEM, one-way 
ANOVA with Bonferroni’s test. *p < 0.05.
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Figure 3. Decreased inflammation, inflammatory mediator production and apoptosis with 6-ECDCA 
pretreatment. (A and B) Representative images of immunostaining for (A) CD4 and (B) TNFα in renal sections 
from (a) sham, (b) I/R and (c) I/R + ECDCA groups (scale bar 50 μm). Note the tubulointerstitial localization 
of CD4+ and TNFa+ inflammatory cells. (C) Levels of mRNA for Tnfα, Il6 and Mcp1 in kidney tissue. n = 6 
mice/group. (D and E) Blood levels of (D) TNFα and (E) MCP1. n = 6 mice/group. (F) Representative images 
of TUNEL staining on renal sections from (a) sham, (b) I/R and (c) I/R + ECDCA groups (scale bar 50 μm). 
Arrows indicate apoptotic bodies. (G) Quantitative analysis of positive TUNEL stained cells per high power 
field. n = 6 mice/group. (H) Levels of Bax, Caspase3 and Bcl2 mRNA in kidney tissue. n = 6 mice/group. Data 
are means ± SEM, one-way ANOVA with Bonferroni’s test. *p < 0.05. (I) Western blot analysis of ICAM and 
cleaved-caspase 3 protein levels in kidney samples of sham, I/R and I/R + ECDCA mice.
www.nature.com/scientificreports/
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FXR activation attenuates renal oxidative and ER stress after I/R. Oxidative stress and lipid per-
oxidation after I/R induce mitochondrial and ER stress. We first investigated whether FXR activation decreased 
oxidative stress in kidneys subjected to I/R by measuring several oxidative stress indicators, urinary H2O2 and 
neutrophil gelatinase-associated lipocalin (NGAL) and kidney myeloperoxidase (MPO) and MDA. Compared 
with the sham group, I/R significantly increased all these indicators (Fig. 4A–D). The levels of these indicators 
were lower, however, with 6-ECDCA pretreatment, suggesting that FXR activation had antioxidant effects. 
4-HNE formation and deoxyguanosine oxidation are common chemical markers of increased ROS. We detected 
4-HNE and 8-oxo-dG by immunostaining (Fig. 4E and F) and found that both were increased in I/R compared 
with sham kidneys (Fig. 4E b and F b). 6-ECDCA pretreatment suppressed ROS production in kidneys subjected 
to I/R, as indicated by decreased staining for 4-HNE and 8-oxo-dG (Fig. 4E c and F c). Quantitative analysis of 
4-HNE and 8-oxo-dG stained cells confirmed decreased ROS production in I/R kidneys, and staining for both 
markers was attenuated by 6-ECDCA pretreatment (Fig. 4H and I). To confirm these results, we examined ROS 
production using H2DCFDA, a specific fluorescence indicator for ROS. Upon cleavage of the acetate groups by 
intracellular esterases, followed by ROS-induced oxidation, the nonfluorescent H2DCFDA is converted to the 
highly fluorescent 2′,7′-dichlorofluorescein (2′,7′-DCF). The fluorescence in renal tissue exposed to I/R was about 
50-fold higher than in controls (Fig. 4G b and J). The clearest changes in ROS production occurred in tubule cells 
Figure 4. Attenuation of I/R-induced oxidative stress by 6-ECDCA treatment. At 24 h after treatment, (A) 
urinary H2O2, (B) urinary NGAL, (C) kidney MPO and (D) kidney MDA were analyzed. n = 6 mice/group. 
Data are means ± SEM, one-way ANOVA with Bonferroni’s test. *p < 0.05. (E and F) Representative images 
of immunostaining for (E) 4-HNE and (F) oxo-8 staining on renal sections from (a) sham, (b) I/R and (c) 
I/R + ECDCA groups (scale bar 50 μm). (G) 2′,7′-DCF staining on renal sections from (a) sham, (b) I/R and (c) 
I/R + ECDCA groups (scale bar 25 μm). (H–J) Quantitative analysis of (H) 4-HNE, (I) oxo-8 and (J) 2′,7′-DCF 
staining per high power field. n = 6 mice/group. Data are means ± SEM, one-way ANOVA with Bonferroni’s 
test. *p < 0.05.
www.nature.com/scientificreports/
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(Fig. 4G b). 6-ECDCA pretreatment resulted in a remarkable decrease in DCF fluorescence after I/R, indicating 
less oxidative stress (Fig. 4G c and J).
Immunostaining for Tomm 20 and SDHA, markers for mitochondria and for mitochondrial respiratory chain 
function, indicated a decreased number of mitochondria and a decreased function of the mitochondrial respira-
tory chain in I/R kidneys (Fig. 5A b and B b). I/R also led to decreased kidney levels of SDHA and Nrf2 proteins, 
detected by western blotting (Fig. S3). This was consistent with electron microscopy, which showed decreased 
mitochondrial numbers, as well as rounded and swollen mitochondria, after I/R (Fig. 5E and F). In contrast, 
mitochondrial numbers and their architecture after I/R were closer to normal with FXR activation (Fig. 5D–F). 
Immunostaining for Grp78, a marker for ER stress, indicated ER dysfunction in the kidneys of I/R-injured mice 
(Fig. 5C b). However, ER stress was attenuated in mice pretreated with 6-ECDCA (Fig. 5C c and G). This indi-
cated that FXR activation was protective against I/R-induced ER stress.
To translate these findings into the clinical setting, we measured markers of oxidative and ER stress in patient 
biopsies from kidneys that had undergone acute ischemic damage (preimplantation biopsies). Immunostaining 
for 4HNE, GRP78 and CHOP produced similar findings to those obtained in the murine I/R model (Fig. 5G a-f). 
Staining for the three markers was predominant in the tubules of kidneys with acute ischemic damage, compared 
with normal kidneys, indicating that increased oxidative and ER stress were induced by I/R in deceased kidney 
donors during kidney transplantation procedures.
FXR activation prevents CKD in mice at 4 months after I/R. In a separate experiment, animals were 
monitored for 16 wk after I/R, with or without 6-ECDCA pretreatment, for comparison with their respective con-
trol groups. As shown in Fig. 6A, during the first 2 mo after AKI recovery, none of the mice subjected to I/R exhib-
ited proteinuria. However, at 4 mo after I/R, there were higher levels of urinary protein in the I/R group compared 
with sham group (Fig. 6B). At the end of the experimental period, the I/R group had significantly increased uri-
nary biomarkers Kim-1 and H2O2 (Fig. 6C and D). These renal functional changes were not observed in the I/R 
group that had been pretreated with 6-ECDCA. Histopathologically, the I/R group had severe structural damage 
comprising glomerulosclerosis and interstitial fibrosis, effects confirmed by PAS and Masson’s trichrome staining 
respectively (Fig. 6E b and F b). However, the 6-ECDCA pretreated group appeared to be protected from such 
pathological changes (Fig. 6E c, I, F c and J). Activation of TGF-β and fibrogenic genes is believed to play a role 
in the progression to CKD. TGF-β and collagen I mRNA levels were increased in the I/R group (Fig. 6K and L). 
Immunostaining for αSMA and collagen I was increased in the I/R injured kidney (Fig. 6G and H). This staining 
pattern was not observed in the 6-ECDCA pretreated group, with only minor fibrosis evident in these mice.
Reduced FXR expression levels have been related to CKD progression. At 4 mo after I/R induced injury, FXR 
expression at the mRNA level was decreased (Fig. 7A). This decrease was confirmed by findings in kidney biopsies 
of patients after cardiac surgery. We examined 25 kidney biopsies from patients who had developed CKD after 
cardiopulmonary bypass, compared with normal controls. Details are summarized in Supplementary Table S1. 
Histological staining for fibrosis and glomerulosclerosis showed that these patients had CKD (Fig. 7D and E). The 
intensity of FXR staining was lower than in patients who did not have kidney damage (Fig. 7F, b compared with 
a). eGFR values were directly correlated with FXR mRNA levels in the kidneys (r2 = 0.401, Fig. 7B). Moreover, 
the incidence of interstitial fibrosis was significantly higher in patients with low FXR mRNA levels (r2 = 0.286, 
Fig. 7C), indicating a negative correlation between FXR expression and CKD progression.
FXR activation increases cell viability and reduces cellular oxidative stress and apoptosis. 
Next, we examined whether FXR expression was decreased in proximal tubular cells exposed to hypoxia. As 
shown in Fig. S4A, the level of FXR protein detected by immunoblotting was significantly lower in cells exposed 
to hypoxia/re-normoxia (H/R) than in those cultured under normoxia. FXR mRNA measurements confirmed its 
decreased expression in hypoxic cells (Fig. S4B).
To better assess the role of FXR activation in preventing I/R induced kidney damage, we cultured primary 
proximal tubular cells from mouse kidney and exposed them to hypoxia, with or without FXR agonists. 6-ECDCA 
treatment successfully activated FXR, as indicated by increased mRNA expression of the FXR-activated genes 
Shp, Ostα and Ostβ (Fig. S4C). Similar results were also obtained in cells treated with GW4064 (Fig. S4C). Next, 
we examined the effects of FXR activation on cell viability. Hypoxia decreased cell viability by about 20%, com-
pared with control cells (Fig. S4D). Pretreatment with 6-ECDCA at both low (1 µM) and high (4 µM) concentra-
tions increased cell survival during hypoxia, consistent with TUNEL staining and quantitative TUNEL analysis 
(Fig. 8A c, B, and S4 D).
Exposure of cells to hypoxia also resulted in oxidative stress, mitochondrial damage and ER stress, as denoted 
by significantly higher signals in assays for intracellular ROS, TMRM, Grp78 and MDA, respectively (Fig. 8B b, C 
b, D b and H). Notably, FXR activation in proximal tubular cells resulted in markedly decreased oxidative stress, 
mitochondrial damage and ER stress in response to hypoxia (Fig. 8B c, C c, D c, H and Fig. S4A). Quantitative 
analysis of ROS-dependent signals under various treatments confirmed decreased ROS levels in 6-ECDCA 
treated cells (Fig. 8F). Changes in levels of ATP and SDHA protein (Fig. 8G and Fig. S4A), both markers of intact 
mitochondrial function, were consistent with the results of TMRM staining. ATP and SDHA protein levels were 
lower in cells exposed to hypoxia compared with normoxia, and both effects were attenuated by 6-ECDCA treat-
ment (Fig. 8G and Fig. S4A). This indicated that FXR activation promoted recovery of mitochondrial function in 
cells exposed to hypoxia.
6-ECDCA attenuates hypoxia-induced oxidative stress through induction of Nrf2-mediated 
antioxidant effects. We previously showed that FXR activation decreased oxidative stress by inducing anti-
oxidant genes in proximal tubular cells28. To confirm this finding, we investigated intracellular glutathione (GSH) 
levels in cells subjected to various treatments. Hypoxia resulted in a 30% decrease in intracellular GSH (Fig. 8I c 
www.nature.com/scientificreports/
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Figure 5. FXR activation protects mitochondrial function and structure and inhibits ER stress during I/R-
induced injury. (A–C) Representative images showing immunostaining for (A) Tomm20, (B) SDHA and (C) 
Grp78 on renal sections from (a) sham, (b) I/R and (c) I/R + ECDCA groups (scale bar 50 μm). Note all three 
protein markers are localized in proximal tubules. (D–F) Quantitative analysis of (D) SDHA staining per 
high power field, quantitative analysis of (E) mitochondrial number and (F) mitochondrial area. n = 6 mice/
group. Data are means ± SEM, one-way ANOVA with Bonferroni’s test. *p < 0.05. (G) Markers for oxidative 
and ER stress in normal and preimplantation human renal biopsy specimens. Shown are representative images 
of immunostaining for (a and d) 4-HNE, and (b and e) GRP78 in kidney specimens obtained from (a and 
b) normal biopsies and (d and e) preimplantation biopsies (magnification 400x). (c and f) CHOP in kidney 
specimens obtained from (c) normal biopsies and (f) preimplantation biopsies (scale bar 100 μm).
www.nature.com/scientificreports/
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and Fig. S5A). Co-treatment of cells undergoing hypoxia with 6-ECDCA attenuated this GSH decrease (Fig. 8I d 
and Fig. S5A). Levels of mRNA for antioxidant genes were also examined in cells exposed to hypoxia. Hypoxia 
decreased mRNA expression of Acox1, Gclm, Gpx1 and Nqo1, all of which were less suppressed in cells also 
co-treated with 6-ECDCA (Fig. S5B). In addition, GSH levels and mRNA expression of Gclm, Sod2 and Nqo1 in 
the kidney cortex of 6-ECDCA treated I/R mice were also increased (Fig. 8K and Fig. S6A to C). Recent studies 
demonstrate the interactions between the FXR signaling pathway and Nrf2-mediated antioxidant effects33, 34. 
Therefore, we examined whether the protective effects of FXR activation and the induction of antioxidant genes 
were mediated through Nrf2. 6-ECDCA reduced hypoxia-induced oxidative stress in the PTCs (Fig. 8J c). When 
the expression of Nrf2 is knocked down, 6-ECDCA failed to exert its effect on the redox state (Fig. 8J d), indicat-
ing a major role of Nrf2 in mediating the inhibitory effect of FXR activation on the oxidative state. As shown by 
Figure 6. Prophylactic 6-ECDCA administration prevents progression to CKD after an I/R induced AKI 
episode. (A) Urinary albumin/creatinine ratios measured every 4 wk after surgery in sham and I/R groups. (B) 
Urinary albumin, (C) Kim1 and (D) H2O2 levels from different treatment groups. n = 6 mice/group. Data are 
means ± SEM, one-way ANOVA with Bonferroni’s test. *p < 0.05. (E) Representative images of PAS staining 
(scale bar 25 μm). (F-H) Representative images of (F) Masson’s trichrome staining and immunostaining for 
(G) αSMA and (H) collagen I in renal sections from (a) sham, (b) I/R and (c) I/R + ECDCA groups (scale bar 
100 μm). αSMA and collagen I are localized in the tubulointerstitial spaces as markers for tubulointerstitial 
fibrosis. (I and J) Bars represent quantitative analysis of the (I) mesangial area and (J) fibrosis area per high 
power field. (K and L) Bars represent (K) TGF-β and (L) collagen I mRNA levels in the kidneys. n = 6 mice/
group. Data are means ± SEM, one-way ANOVA with Bonferroni’s test. *p < 0.05.
www.nature.com/scientificreports/
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western blot analysis, FXR activation induced Nrf2 protein levels in the nuclei of PTCs treated with 6-ECDCA 
(Fig. S7). Silencing of FXR in PTCs transfected with FXR siRNA blocked this induction (Fig. S7). Consistent 
with this, immunostaining for Nrf2 showed Nrf2 translocation in the proximal tubule cells of mouse kidney with 
6-ECDCA treatment (Fig. S8 C and F respectively). Moreover, both Nrf2 and FXR siRNA blocked the induction 
of Gclm, a target gene of Nrf2 (Fig. S9). Therefore, FXR activation protected kidney proximal tubular cells by 
inducing Nrf2-mediated antioxidant pathways.
Discussion
In this study, we demonstrated that pretreatment with the FXR agonist 6-ECDCA protected against renal I/R 
injury. After I/R, 6-ECDCA pretreated mice displayed significantly better renal function, less histological tubular 
damage and reduced inflammation, compared with those subjected to I/R alone. These protective effects were 
associated with ameliorated oxidative stress, as manifested by an increased antioxidant capacity, that is, higher 
GSH and lower ROS levels. Consistent with our findings in mice, our analysis of human renal biopsy samples 
showed greater oxidative and ER stress in kidneys that had undergone ischemia. Moreover, FXR expression was 
negatively correlated with the progression of tubular interstitial fibrosis and CKD, observed at longer time peri-
ods after ischemic damage. Thus, FXR activation might represent a novel protective strategy against I/R-induced 
kidney damage over both short and long time periods.
Figure 7. FXR mRNA expression is inversely correlated with CKD progression. (A) FXR mRNA expression in 
kidney samples from sham and I/R mice 16 wk after surgery. (B) FXR mRNA expression in human kidney 
biopsies was directly correlated with eGFR. (C) FXR mRNA expression in human kidney biopsies was inversely 
correlated with interstitial fibrosis, as determined by histology. The lowest level of FXR mRNA expression was 
set to 1 (shown as ). (D and E) Representative images of (D) Masson’s trichrome staining and (E) PAS staining 
in renal biopsy sections from (a) normal subjects and (b) patients with CKD (scale bar 20 μm). (F) 
immunostaining for FXR in renal biopsy sections from (a) normal subjects and (b) patients with CKD (scale bar 
100 μm).
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Figure 8. Effects of FXR activation on hypoxia-induced oxidative stress in primary cultured proximal tubular 
cells (PTCs). H/R, hypoxia/re-normoxia. (A–D) Representative images of (A) TUNEL staining, (B) CellROX 
staining, (C) TMRM staining and (D) immunostaining for Grp78 on PTCs treated with vehicle under (a) 
normoxia and at 24 h after exposure to hypoxia (b) without 6-ECDCA treatment or (c) with 6-ECDCA 
treatment (scale bar 50 μm). Staining colors correspond to the labels on the left side of each panel. Cells 
were counterstained with hematoxylin (blue) or DAPI (blue). (E–H) Quantitative analysis of positive (E) 
TUNEL staining and (F) ROS staining per high power field and (G) ATP production and (H) intracellular 
MDA in PTCs. n = 4/group. Data are means ± SEM, one-way ANOVA with Bonferroni’s test. *p < 0.05. (I) 
Representative images of GSH detection in PTCs with different treatments (scale bar 50 μm). H/R, hypoxia/
re-normoxia. Staining colors correspond to the labels on the left side of each panel. Cells were counterstained 
with ActinGreen (green). (J) Representative images of CellROX staining of PTCs treated as indicated (scale bar 
100 μm).
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Repression of FXR was reported to contribute to biliary injury in liver grafts35. In vitro data suggested that 
hypoxia downregulated FXR via a p38MAPK dependent pathway36. FXR expression was inversely correlated 
with the progression of obesity and diabetic nephropathy37, 38. It was also reported that the FXR signaling pathway 
was repressed during kidney I/R injury39. Consistent with these reports, our data showed that FXR expression 
was substantially decreased during the early period after I/R and that its expression level was inversely correlated 
with CKD progression. The beneficial effects of FXR activation in modulating kidney injury were demonstrated 
in our previous studies in obese mice, using obeticholic acid28. FXR activation proved to be beneficial against 
obesity and diabetes-induced kidney damage because of its antioxidant effects. The role of FXR in modulating 
lipid metabolism and renal disease was also demonstrated in STZ diabetic mice, mice with diet-induced obesity 
and db/db mice40–42. Our present findings not only showed involvement of FXR in I/R induced injury but also 
revealed a more profound role for FXR in renal pathophysiology related to oxidative stress.
In our study, CKD was induced using a single episode of AKI in mice and we obtained evidence that an 
early intervention, administration of 6-ECDCA, was important for preventing or slowing CKD progression. Our 
data showed that FXR activation effectively prevented the transition to CKD. The I/R group developed CKD, 
characterized by renal dysfunction, glomerulosclerosis and tubulointerstitial fibrosis (Fig. 7). It was previously 
believed that patients recovering from an AKI episode experienced no further deterioration of kidney function. 
However, AKI is now known to be an independent risk factor for development of CKD and transition from 
CKD to end-stage renal disease43–45. It was estimated that 20% of patients experiencing an episode of AKI would 
develop CKD within 3 years46. Recent studies showed that progression to CKD from ischemia-induced AKI 
depended on the extent of tubular epithelial death mediated by the TNFα pathway47 and on the sustained acti-
vation of Wnt/beta-catenin signaling48. These abnormalities certainly accelerated deterioration of the functional 
nephrons. In our study, FXR activation decreased TNFα levels and the degree of fibrosis in I/R injured kidneys. 
Thus, it is possible that the 6-ECDCA treated group had fewer damaged nephrons, and that this was reflected in 
better renal function and preservation of glomerular structure, as compared with the group receiving only I/R.
Previous studies proved a substantial protective role for FXR activation in mitochondrial membrane perox-
idation systems, through its antioxidant and free radical-scavenging activities28, 49–51. FXR may also protect the 
mitochondria by interacting with FoxO3a52, Nrf253 and AMPK54 pathways, all of which are important for mito-
chondrial function. Our data showed that FXR activation restored the oxidative balance, improved mitochondrial 
function and reduced ER stress in kidneys subjected to I/R. Moreover, we demonstrated that Nrf2 mediated the 
protective effects of FXR against oxidative stress. Silencing of Nrf2 blocked the protective effect of 6-ECDCA in 
proximal tubule cells exposed to hypoxia (Fig. 9). Based on these findings, FXR is a potential target for future 
therapeutic approaches in patients suffering from kidney ischemia secondary to cardiovascular surgery and kid-
ney transplantation as well as in other kidney impairments.
Sustained leukocyte accumulation and activation inside the kidney could extend periods of ischemia and 
may induce direct tubular and endothelial cell damage by the release of ROS. Although the impact of FXR acti-
vation on leukocyte infiltration in the I/R kidney was not explored in this study, several lines of evidence indicate 
that FXR activation could also reduce ROS through regulating leukocyte activation. Several studies showed that 
FXR has anti-inflammatory properties and that these properties are potentially beneficial for treating various 
inflammatory diseases. The first such evidence was derived from the observation that FXR inhibited NFκB, the 
downstream pathway regulated by TNFα55. FXR activation reduced hepatic inflammation and fibrosis in a mouse 
model of non-alcoholic steatohepatitis56, whereas FXR deficiency caused increased hepatic inflammation and 
fibrosis57. FXR also inhibited expression of profibrotic growth factors and proinflammatory cytokines in both in 
vivo and in vitro studies40, consistent with our findings. Moreover, a recent study demonstrates that dual FXR and 
Figure 9. Scheme showing that hypoxia promotes ROS through inducing inflammation and epithelial 
cell damage. FXR activation inhibits I/R-induced ROS by reducing inflammatory cytokines and inducing 
antioxidant molecules in the proximal tubule cells.
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TGF5 activation induces the transition of macrophages from Ly6Chigh into Ly6Clow phenotype and increases 
IL-10 production58, indicating potential regulatory effects of FXR on macrophage activation and release of ROS 
(Fig. 8K).
In conclusion, this study illustrates that the damage incurred by the kidney after an I/R episode leads to 
increased ROS levels and associated mitochondrial and ER stress. Activation of the bile acid receptor FXR reduces 
renal inflammation and apoptosis, lowers ROS levels, and protects kidney mitochondria in mice subjected to I/R. 
Moreover, FXR activation prevents oxidative stress-induced mitochondrial damage by upregulating antioxidant 
pathways and controlling glutathione metabolism, providing several likely explanations for its beneficial effect.
Methods
Animals. Female C57/BJ mice, aged 6 wk, were randomly assigned to I/R or sham procedures. They were 
divided into 3 groups of 6 animals each: sham, I/R and I/R + ECDCA. AKI was induced using unilateral with 
contralateral nephrectomy, as previously described59. For 6-ECDCA pretreatment, mice were injected intraperi-
toneally (i.p.) with 6-ECDCA (5 mg/kg, ab144246, Abcam, Cambridge, UK) 24 h before ischemia. In another set 
of experiments, mice received 6-ECDCA (5 mg/kg, i.p.) at 8 or 2 h before ischemia or 30 min after I/R. To model 
I/R induced CKD, mice were maintained in their housing cages and fed a normal diet for 16 wk. All mice were 
killed under anesthesia at different times after surgery. Kidneys were harvested for further analysis.
Measurements in plasma and urine samples. Urinary albumin and creatinine concentrations were 
measured in the resulting urine samples with the albumin mouse ELISA kit (ab108792, Abcam, Cambridge, UK) 
and creatinine assay kit (ab65340, Abcam), respectively. Urinary H2O2 levels were measured using the Amplex 
Red H2O2 assay kit (A12214, Invitrogen, CA, USA). Plasma creatinine and blood urea nitrogen (BUN) levels 
were measured with a creatinine assay kit (ab65340, Abcam) and the QuantiChrom™ Urea Assay Kit (DIUR-100, 
BioAssay System, Hayward, CA, USA), respectively.
Renal pathological assessments and immunostaining. Tissue sections were stained with hema-
toxylin and eosin (HE), Periodic acid-Schiff ’s (PAS) and Masson’s trichrome stains using standard protocols. 
The mesangial area was determined from the PAS stained sections and the fibrotic area from the Masson’s tri-
chrome stained sections as previously described28. The antibodies used in this study were those against FXR (sc-
13063, Santa Cruz), Grp78 (ab21685, Abcam), Chop (ab59396, Abcam), 4-hydroxynonenal (4-HNE, ab46545, 
Abcam), Kim-1 (ab78494, Abcam), 8-oxo-2′-deoxyguanosine (8-oxo-dG, ab64548, Abcam), SDHA (#11998, 
CellSignaling, Danvers, MA, USA), tumor necrosis factor (TNF, ab6671, Abcam), CD4 (sc-7219, Santa Cruz, 
Dallas, TX, USA), aSMA (NBP1-30894, Novus Biologicals, Littleton, CO, USA) and Collagen I (ColI, NB600-408, 
Novus Biologicals). TUNEL staining on kidney paraffin sections was performed with an ApopTag kit (Millipore, 
Billerica, MA, USA), according to the manufacturer’s instructions.
ROS determination in kidneys. Fresh renal cortex tissue slices, approximately 200 μm thick, were cut 
with a blade and placed into Hanks solution containing 10 mM Hepes-NaOH, pH 7.4 and the fluorescent ROS 
probe. Kidney slices were loaded with 10 μM 2′,7′-dichlorodihydrofluorescein diacetate (2′,7′-DCFDA, Molecular 
Probes, Inc., Eugene, Oregon, USA) for 10 min at room temperature followed by a 5 min wash in Hanks solution. 
A threshold series of images was processed with ImageJ software (National Institutes of Health, Bethesda, MD, 
USA) to determine relative intensities of 2′,7′-dichlorohydrofluorescein (2′,7′-DCF).
Isolation of primary proximal tubular cells and cell staining. Primary proximal tubular cells were 
isolated and stained as described previously28. After treatments, cells were fixed and incubated with primary 
antibodies, as indicated, at 4 °C overnight. The cells were then washed and incubated with the appropriate sec-
ondary antibody for 1 h in the dark. Antibodies against Grp78 were purchased from Abcam. For intracellular ROS 
detection (CellRox, Life Technologies), mitochondrial membrane potential (∆Ψm) detection (TMRM, Molecular 
Probes), glutathione detection (ThioTracker Violet, Life Technologies), and TUNEL staining (ApopTag, 
Millipore), cells were processed according to the manufacturer’s protocols. Cells were analyzed for malonyldial-
dehyde (MDA) (ab118970; Abcam), ATP (CellTiter-Glo, Promega) and GSH (ApoGSH, BioVision) using specific 
assay kits, according to the manufacturers’ instructions.
Hypoxia/Re-normoxia model in proximal tubular cells. Prior to the procedure, cells were cultured 
to 70%–80% confluence, then serum deprived overnight. Next the effects of hypoxia on oxidative and ER stress 
in primary cultured cells were investigated under low oxygen (1% O2) for 12 h. Where indicated, cells were pre-
treated with 1 μM GW4064 or 1 μM 6-ECDCA for 4 h prior to hypoxia treatment. For the RNA interference 
experiment, cells were pretreated with Nrf2 or FXR siRNA (100 nM) for 24 hours before exposure to hypoxia.
Isolation of RNA from kidney tissue and cells and quantification of transcript levels. Total 
RNA was prepared using Trizol (Invitrogen, CA, USA). The mRNA was quantified based on absorbance at 
260 nm. After DNAse (Promega) treatment, 2 μg total RNA was reverse transcribed using oligo-dT priming and 
Superscript II (Invitrogen). First-strand complementary DNA was used as the template for real-time polymerase 
chain reaction analysis with TaqMan master mix and primers (Applied Biosystems, CA, USA). Transcript levels, 
determined in two independent complementary DNA preparations, were calculated and expressed relative to 
levels of RNA for the housekeeping gene villin.
Western blotting. Protein lysates (20 μg protein) of kidney tissue or cells were separated by SDS-PAGE and 
blotted on polyvinylidene difluoride membranes (Millipore). The membranes were incubated overnight at 4 °C 
with the respective primary antibodies and secondary antibodies accordingly. Staining was then developed using 
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the ECL Plus detection system (Amersham Biosciences, Little Chalfont, UK). The antibody against villin was from 
Chemicom (MAB1639a, Toronto, Canada), anti-tubulin (T6074) was from Sigma-Aldrich (Buchs, Switzerland), 
anti-Grp78 (ab21685) was from Abcam, anti-ICAM (sc-1511), anti-FXR (sc-13063) and anti-Nrf2 (sc-722) were 
from Santa Cruz and anti-SDHA (#11998) and anti- cleaved caspase 3 (#9661) were from CellSignaling (Danvers, 
MA, USA).
Study approval. All animal experiments conformed to both Swiss and Chinese animal protection laws and 
were approved by the Scientific Animal Study Committee of Shandong University, Jinan, China (study number 
2015064). The human study was conducted according to the Declaration of Helsinki guidelines regarding ethical 
principles for medical research involving human subjects. All patients provided written informed consent and the 
study protocol was approved by the Scientific Ethical Committee of Shandong University, Jinan, China, where the 
patients were based (license number SDU2007011 and SDU2015033).
Statistics. Data are expressed as means ± SEM. For data relating to baseline characteristics and histological 
analysis, groups were compared by one-way ANOVA followed by Bonferroni’s test. For data relating to demo-
graphics and clinical characteristics, groups were compared by one-way ANOVA followed by Bonferroni’s test or 
by Mann–Whitney U test. Statistical analyses were performed using GraphPad software (CA, USA).
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